Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

E. Anders Kolb, Richard Gorlick, Stephen T. Keir, John M. Maris, Min H. Kang, C. Patrick Reynolds, Richard B. Lock, Hernan Carol, Jianrong Wu, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith

Resultado de la investigación: Articlerevisión exhaustiva

8 Citas (Scopus)

Resumen

BAL101553 is a highly water soluble prodrug of BAL27862 that arrests tumor cell proliferation and induces cell death in cancer cells through disruption of the microtubule network. In vitro BAL27862 demonstrated potent activity, with the median relative IC50 (rIC50) of 13.8nM (range 5.4-25.2nM). The in vitro activity of BAL27862 against the PPTP cell lines is distinctive from that previously described for vincristine. BAL101553 induced significant differences in EFS distribution compared to control in 16 of 30 (53%) solid tumor xenografts and in two of four (67%) of the evaluable ALL xenografts. No objective responses were observed.

Idioma originalEnglish (US)
Páginas (desde-hasta)1106-1109
Número de páginas4
PublicaciónPediatric Blood and Cancer
Volumen62
N.º6
DOI
EstadoPublished - jun. 1 2015
Publicado de forma externa

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Huella

Profundice en los temas de investigación de 'Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program'. En conjunto forman una huella única.

Citar esto